Literature DB >> 20657168

Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma.

Anne M Delany1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20657168      PMCID: PMC3230283          DOI: 10.4161/cbt.10.1.12452

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  20 in total

1.  Osteopontin expression in ductal adenocarcinomas and undifferentiated carcinomas of the pancreas.

Authors:  R Sedivy; K Peters; G Klöppel
Journal:  Virchows Arch       Date:  2004-11-26       Impact factor: 4.064

Review 2.  Tumor-stroma interactions in pancreatic ductal adenocarcinoma.

Authors:  Daruka Mahadevan; Daniel D Von Hoff
Journal:  Mol Cancer Ther       Date:  2007-04-03       Impact factor: 6.261

3.  Osteonectin influences growth and invasion of pancreatic cancer cells.

Authors:  Ahmed Guweidhi; Jörg Kleeff; Hassan Adwan; Nathalia A Giese; Moritz N Wente; Thomas Giese; Markus W Büchler; Martin R Berger; Helmut Friess
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

4.  Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions.

Authors:  A Kolb; J Kleeff; A Guweidhi; I Esposito; N A Giese; H Adwan; T Giese; M W Büchler; M R Berger; H Friess
Journal:  Cancer Biol Ther       Date:  2005-07-05       Impact factor: 4.742

5.  Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma.

Authors:  Shanna A Arnold; Lee B Rivera; Andrew F Miller; Juliet G Carbon; Sean P Dineen; Yang Xie; Diego H Castrillon; E Helene Sage; Pauli Puolakkainen; Amy D Bradshaw; Rolf A Brekken
Journal:  Dis Model Mech       Date:  2009-12-09       Impact factor: 5.758

6.  Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma.

Authors:  Jennifer Sullivan; Laurel Blair; Amer Alnajar; Tamer Aziz; Chee Yuan Ng; Galina Chipitsyna; Qiaoke Gong; Agnes Witkiewicz; Georg F Weber; David T Denhardt; Charles J Yeo; Hwyda A Arafat
Journal:  Surgery       Date:  2009-08       Impact factor: 3.982

7.  Osteopontin expression and distribution in human carcinomas.

Authors:  L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

Review 8.  Osteopontin as a target for cancer therapy.

Authors:  Nicholas I F Johnston; Vignesh Kumar Gunasekharan; Amod Ravindranath; Ciara O'Connell; Patrick G Johnston; Mohamed K El-Tanani
Journal:  Front Biosci       Date:  2008-05-01

9.  The role of SPARC in extracellular matrix assembly.

Authors:  Amy D Bradshaw
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

10.  SPARC: a matricellular regulator of tumorigenesis.

Authors:  Shanna A Arnold; Rolf A Brekken
Journal:  J Cell Commun Signal       Date:  2009-10-07       Impact factor: 5.782

View more
  7 in total

Review 1.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

2.  Prognostic biomarkers related to tumoral microenvironment in pancreatic ductal adenocarcinoma: a systematic review.

Authors:  Alina Liliana Constantin; Irina Mihaela Cazacu; Cezar Stroescu; Cătălin Copăescu; Adrian Săftoiu
Journal:  Rom J Morphol Embryol       Date:  2021 Jul-Sep       Impact factor: 0.833

Review 3.  First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.

Authors:  Neha Gupta; Hassan Hatoum; Grace K Dy
Journal:  Int J Nanomedicine       Date:  2013-12-24

4.  α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study.

Authors:  M Sinn; C Denkert; J K Striefler; U Pelzer; J M Stieler; M Bahra; P Lohneis; B Dörken; H Oettle; H Riess; B V Sinn
Journal:  Br J Cancer       Date:  2014-10-14       Impact factor: 7.640

5.  Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer.

Authors:  K Adam Morrow; Shamik Das; Erhong Meng; Mitchell E Menezes; Sarah K Bailey; Brandon J Metge; Donald J Buchsbaum; Rajeev S Samant; Lalita A Shevde
Journal:  Oncotarget       Date:  2016-04-05

6.  Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma.

Authors:  Sven H Loosen; Pia Hoening; Niklas Puethe; Mark Luedde; Martina Spehlmann; Tom F Ulmer; David V Cardenas; Sanchari Roy; Frank Tacke; Christian Trautwein; Ulf P Neumann; Tom Luedde; Christoph Roderburg
Journal:  Sci Rep       Date:  2019-02-06       Impact factor: 4.379

7.  Understanding the molecular association between hyperkalemia and lung squamous cell carcinomas.

Authors:  Xianping Meng; Hongyan Lu; Xia Jiang; Bin Huang; Song Wu; Guiping Yu; Hongbao Cao
Journal:  BMC Med Genet       Date:  2020-10-22       Impact factor: 2.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.